I'll just say three things quickly. One is that it will affect patients immediately within that time period, because patients who are part of that genetic testing and imaging will be eligible for different options for therapy and different kinds of therapy that will benefit them immediately. There is an untapped opportunity to help patients today that is part of unfunded care.
Second, it's going to create a market for innovation. The capture of data on patients across the country, including their outcomes, will create an opportunity for innovation across the country and create more partnership in intersection with industry, and create more industry around it.
In Toronto we see huge investments in artificial intelligence and in data science. What this community is looking for is good data. In the health care system in Canada the kinds of data that we can create provide an enormous opportunity for this other part of the industry that the entire world is investing in.
The third thing is that the creation of this, at the end of the five years, is going to establish a new network, a new system in Canada for the coordination of cancer centres. It will be a legacy through which all cancer centres across the country will have an opportunity to tap into and benefit from the sharing and the data, and we will set up a system whereby we can continue to learn from our patients, going forward.